Danoprevir: all 28 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedNCT03020095Phase 2Results posted
- Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3Results posted
- Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedNCT03020004Phase 2Results posted
- Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionCompletedNCT04345276Phase 4
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedNCT03362814Phase 2/3
- Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedNCT03288636Phase 1
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03020134Phase 1
- Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03019991Phase 1
- A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without CirrhosisCompletedNCT01749150Phase 2
- A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy ControlsCompletedNCT01714154Phase 1
- A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy VolunteersCompletedNCT01654211Phase 1
- A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy VolunteersCompletedNCT01592318Phase 1
- A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or AtazanavirCompletedNCT01592305Phase 1
- A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy VolunteersCompletedNCT01588002Phase 1
- A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy VolunteersCompletedNCT01531647Phase 1
- A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy VolunteersCompletedNCT01519336Phase 1
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy VolunteersCompletedNCT01514968Phase 1
- A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy VolunteersCompletedNCT01483729Phase 1
- A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy VolunteersCompletedNCT01418274Phase 1
- A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy SubjectsCompletedNCT01398293Phase 1
- A Study on the Interaction Between Danoprevir/Ritonavir and MethadoneCompletedNCT01389544Phase 1
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedNCT01278134Phase 2
- A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01220947Phase 2
- A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic ImpairmentCompletedNCT01185873Phase 1
- A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1CompletedNCT01185860Phase 1
- A Study of RO5190591 (Danoprevir) in Healthy VolunteersCompletedNCT01164488Phase 1
- A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT00963885Phase 2
- A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C PatientsCompletedNCT00801255Phase 1